ReviewJournal of food and drug analysis2017
Recent advances in oral delivery of drugs and bioactive natural products using solid lipid nanoparticles as the carriers.
Review in Journal of food and drug analysis, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed.
- Resolvin E1 promotes the resolution of inflammation and enhances myogenic responses during aged skeletal muscle regeneration.GeroScience · 2026Article
- Targeted delivery of postbiotics: oral, intradermal, and intravenous models.Folia microbiologica · 2026Article
- Computational and Molecular Dynamics Insights into the Antithrombotic Mechanism of Triterpenes Derived fromMolecules (Basel, Switzerland) · 2026Article
- Targeted nanoliposomal nutrient delivery for human health.World journal of gastrointestinal pharmacology and therapeutics · 2025Review
- Strategies to Overcome Challenges in Formulating Tablets from Dried Plant Extracts: a Comprehensive Review.AAPS PharmSciTech · 2025Review
- Nano-interventions for dengue: a comprehensive review of control, detection and treatment strategies.Inflammopharmacology · 2025Review
- Development and Characterization of a Cationic Polyurethane Carrier for Enhanced Topical DNA Delivery.Drug design, development and therapy · 2025Article
- Solid Lipid Nanoparticles for the Management of Hypertension: Advancements and Challenges.Current pharmaceutical design · 2025Review
- Targeting Disulfidptosis with Potentially Bioactive Natural Products in Metabolic Cancer Therapy.Metabolites · 2024Review
- Solid Lipid Nanoparticles Loaded with Dexamethasone Palmitate for Pulmonary Inflammation Treatment by Nebulization Approach.Pharmaceutics · 2024Article
- Article
- Oral Delivery of the Vancomycin Derivative FU002 by a Surface-Modified Liposomal Nanocarrier.Advanced healthcare materials · 2024Article
- Empowering Naringin's Anti-Inflammatory Effects through Nanoencapsulation.International journal of molecular sciences · 2024Article
- Recent advances in oral insulin delivery technologies.Journal of controlled release : official journal of the Controlled Release Society · 2024Article
- Article
- Potential of Natural Products as Therapeutic Agents for Inflammatory Diseases.Anti-inflammatory & anti-allergy agents in medicinal chemistry · 2024Review
- Targeted nanodelivery systems for personalized cancer therapy.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2024Review
- Newly designed nanoparticle-drug delivery systems againstInternational journal of clinical and experimental pathology · 2024Review
- Exploring the Prospective of Curcumin-loaded Nanomedicine in Brain Cancer Therapy: An Overview of Recent Updates and Patented Nanoformulations.Recent patents on nanotechnology · 2024Review
- Polysorbate 80 surface modified SLNs of formoterol suppress SNCA gene and mitochondrial oxidative stress in mice model of Parkinson's disease.Scientific reports · 2023Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemical and enzymatic barriers in the gastrointestinal (GI) tract hamper the oral delivery of many labile drugs. The GI epithelium also contributes to poor permeability for numerous drugs. Drugs with poor aqueous solubility have difficulty dissolving in the GI tract, resulting in low bioavailability. Nanomedicine provides an opportunity to improve the delivery efficiency of orally administered drugs. Solid lipid nanoparticles (SLNs) are categorized as a new generation of lipid nanoparticles consisting of a complete solid lipid matrix. SLNs used for oral administration offer several benefits over conventional formulations, including increased solubility, enhanced stability, improved epithelium permeability and bioavailability, prolonged half-life, tissue targeting, and minimal side effects. The nontoxic excipients and sophisticated material engineering of SLNs tailor the controllable physicochemical properties of the nanoparticles for GI penetration via mucosal or lymphatic transport. In this review, we highlight the recent progress in the development of SLNs for disease treatment. Recent application of oral SLNs includes therapies for cancers, central nervous system-related disorders, cardiovascular-related diseases, infection, diabetes, and osteoporosis. In addition to drugs that may be active cargos in SLNs, some natural compounds with pharmacological activity are also suitable for SLN encapsulation to enhance oral bioavailability. In this article, we systematically introduce the concepts and amelioration mechanisms of the nanomedical techniques for drug- and natural compound-loaded SLNs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.